肾细胞癌分子靶向治疗的研究进展

Advances in targeted molecular therapy of renal cell carcinoma

近年来肾细胞癌(RCC)分子生物学研究取得了很大的进展,已确认的信号通路包括血管内皮生长因子和磷脂酰肌醇3激酶(PI3K)-Akt-哺乳动物雷帕霉素靶蛋白(mTOR)通路等。RCC的靶向治疗已成为研究热点,新型靶向药物sunitinib、sorafenib、temsirolimus和bevacizumab在临床前期和临床试验中的疗效令人鼓舞。

In recent years, there is great progress in molecular biology research of renal cell carcinoma （RCC）, the signaling pathways including vascular endothelial growth factor and phosphatidylinositol-3 kinase （PI3K）- Akt -mammalian protein target of rapamycin （mTOR） have been confirmed. The targeted molecular therapy of RCC has become a focus research. The therapeutic effect of novel targeted therapy agents such as sunitinib, sorafenib, temsirolimus and bevacizumab is encouraging in pre-clinical and clinical trials.